Jing Liang: Redefining Success in Long Term Cancer Drug Development
Oncologists and entrepreneurs are debating the efficacy of different clinical trial designs for cancer drug development. The discussion centers on whether large crossover overall survival trials are superior to smaller objective response rate trials for regulatory approval.
Why it matters
The debate influences how quickly new cancer treatments reach patients and how regulatory bodies evaluate drug efficacy.
Jing Liang , Entrepreneur, Drug hunter, shared on X :
”I think Dr. Kurzrock is making a very important point that some people are missing.
I asked Claude to create an illustration of what I mean. For a given cancer, the incidence is relatively fixed, which means the clinical trial patient pool is relatively fixed. Same pool of patients buys you 24 small ORR trials or 2 big crossover OS trials. Also, a big crossover OS RCT does not guarantee to give you a better drug – which is the point Dr. Kurzrock is making. Over lets say 15 years, as a public policy, what regulatory approval standards will give you the greatest improvement in cancer care ?
This is completely different from the question:
‘ which trial design will give you the most accurate assessment of an individual drug’s efficacy ?’
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in